In this report, we describe anti-atherogenic effects of Oxy210, a non-endogenous (man-made) oxysterol-based drug candidate, which we previously evaluated as a prospective NASH therapeutic using APOE*3-Leiden.CETP mice, a mouse model for NASH and atherosclerosis in which symptoms are induced by consumption of a high-fat high-cholesterol “Western” diet (WD) [48,49]. Here, APOE is linked to metabolic dysfunction-associated steatohepatitis.